Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

Fig. 2

A Waterfall plot for BICR-assessed tumor best percentage change from baseline in FAS. The dashed line at 20% represents the boundary for the determination of PD, and the dashed line at − 30% represents the boundary for the determination of PR. Color code: orange for PR; brown for SD; blue for PD. B Forest plot for subgroups of patients having BICR-assessed objective responses in FAS. *Other includes one patient with G719X and S768I mutations, and one patient with only L861Q mutation. The Cobas® EGFR Mutation Test, Version 2, Roche Diagnostics, South Branchburg, NJ, USA, was used for EGFR mutations detection, which was not able to further confirm this patient’s specific G719X type. Abbreviation: FAS, full analysis set; CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; PS, performance status; BICR, blinded independent central review; ORR, objective response rate; DCR, disease control rate; CI, confidence interval; PR, partial response; SD, stable disease; PD, progressive disease

Back to article page